Elizabeth Kidd

ORCID: 0000-0003-4749-4098 · 14 papers in corpus · active 2024

Study types

  • preprint 8
  • supplementary-materials 6
preprint 2024
·doi:10.1158/1078-0432.26134341.v1

Supplemental Figure 1: Kaplan Meier Survival Curves by TCGA Molecular Subtype

preprint 2024
·doi:10.1158/1078-0432.26134341

Supplemental Figure 1: Kaplan Meier Survival Curves by TCGA Molecular Subtype

preprint 2024
·doi:10.1158/1078-0432.26134338.v1

Supplemental Figure 2: Schoenfeld’s test of proportional hazards for multivariate Cox analysis including CINSARC and EcoTyper Classifiers.

preprint 2024
·doi:10.1158/1078-0432.26134338

Supplemental Figure 2: Schoenfeld’s test of proportional hazards for multivariate Cox analysis including CINSARC and EcoTyper Classifiers.

preprint 2024
·doi:10.1158/1078-0432.26134335

Supplemental Figure 3: EERI Values in TCGA Subtypes. A) The Stanford-EEC cohort and subgroups. B) The TCGA-UCEC cohort and subgroups. P-values generated by Whitney-Mann U test. Error bars represent 95% confidence intervals.

preprint 2024
·doi:10.1158/1078-0432.26134335.v1

Supplemental Figure 3: EERI Values in TCGA Subtypes. A) The Stanford-EEC cohort and subgroups. B) The TCGA-UCEC cohort and subgroups. P-values generated by Whitney-Mann U test. Error bars represent 95% confidence intervals.

preprint 2024
·doi:10.1158/1078-0432.26134332.v1

Supplemental Figure 4: Recurrence Free Survival stratified by EERI score for Stages I-IV disease in the TCGA-UCEC Cohort. Patients with EEC by stage at diagnosis. Patients were included with more than 1 year of follow-up and known endometri…

preprint 2024
·doi:10.1158/1078-0432.26134332

Supplemental Figure 4: Recurrence Free Survival stratified by EERI score for Stages I-IV disease in the TCGA-UCEC Cohort. Patients with EEC by stage at diagnosis. Patients were included with more than 1 year of follow-up and known endometri…

supplementary-materials 2024
·doi:10.1158/1078-0432.26134329.v1

Supplemental Table 1: Genes used in EERI listed by prognostic impact.

supplementary-materials 2024
·doi:10.1158/1078-0432.26134329

Supplemental Table 1: Genes used in EERI listed by prognostic impact.

supplementary-materials 2024
·doi:10.1158/1078-0432.26134326

Supplemental Table 2: Clinical and Pathologic Variables of Cases and EERI False Negatives in both the Stanford-EEC cases and TCGA-UCEC recurrent patients

supplementary-materials 2024
·doi:10.1158/1078-0432.26134326.v1

Supplemental Table 2: Clinical and Pathologic Variables of Cases and EERI False Negatives in both the Stanford-EEC cases and TCGA-UCEC recurrent patients

supplementary-materials 2024
·doi:10.1158/1078-0432.26134323.v1

Supplemental Table 3: Clinical and Pathologic Variables of Controls and EERI False Positives in both the Stanford-EEC controls and TCGA-UCEC non-recurrent patients

supplementary-materials 2024
·doi:10.1158/1078-0432.26134323

Supplemental Table 3: Clinical and Pathologic Variables of Controls and EERI False Positives in both the Stanford-EEC controls and TCGA-UCEC non-recurrent patients